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Abstract
Objective: In a prospective multicenter trial, it was our
intention to elucidate clinical prognostic factors of semi-
nomas with special reference to the importance of hu-
man chorionic gonadotropin (HCG) elevations in histo-
logically pure seminomas. Methods: Together with 96
participating urological departments in Germany, Aus-
tria, and Switzerland, we recruited 803 seminoma pa-
tients between 1986 and 1991. Out of 726 evaluable
cases, 378 had elevated, while 348 had normal HCG val-
ues in the cubital vein. Histology was reviewed by two
reference pathologists. HCG levels were determined in
local laboratories and in a study laboratory. Standard
therapy was defined as radiotherapy in stages I (30 Gy)
and IIA/B (36 Gy) to the paraaortal and the ispilateral
(stage I) and bilateral (stage IIA/B) iliac lymph nodes;
higher stages received polychemotherapy and surgery
in case of residual tumor masses. Statistics included chi-
square tests, linear Cox regression, and log-rank test.
Results: The HCG elevation is associated with a larger
tumor mass (primary tumor and/or metastases). HCG-
positive and HCG-negative seminomas had no different
prognostic outcome after standard therapy. The overall
relapse rate of 6% and the survival rate of 98% after 36
months (median) indicate an excellent prognosis. The
calculation of the relative risk of developing a relapse
discovered only stage of the disease and elevation of the
lactate dehydrogenase concentration and its prolonged
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marker decay as independent prognostic factors for sem-
inomas. A more detailed analysis of the prognostic sig-
nificance of the stage revealed that the high relapse rate
in stage IIB seminomas after radiotherapy (24%) is re-
sponsible for this result. Conclusions: We conclude that
HCG-positive seminomas do not represent a special enti-
ty. Provided standard therapy is applied, HCG has no
influence on the prognosis. Patients with stage IIB dis-
ease should be treated with chemotherapy because of
the demonstrated higher relapse rate outside the retro-
peritoneum.
Copyright © 1999 S. Karger AG, Basel
Introduction
Elevations of human chorionic gonadotropin (HCG)
levels in histologically pure seminomas lead to conjec-
tures about the histological origin, the prognosis, and the
adequate therapy of these tumors.
While elevated ·-fetoprotein (AFP) levels are inconsis-
tent with the diagnosis of a pure seminoma [1], immuno-
histochemistry was able to demonstrate syncytiotropho-
blastic giant cells and even mononuclear seminoma cells
to be the origin of the HCG production [2, 3]. Moreover,
marker investigations of blood samples of the testicular
vein demonstrated that nearly all seminomas are able to
produce HCG [4]. Reviewing the published results of oth-
er investigators, we revealed an incidence of about 20% of
the seminomas with elevated HCG serum titers in the
cubital vein and that a positive immunohistological stain-
ing was successful in only 14% of the cases [5].
The supposed poor prognosis of HCG-positive semi-
nomas was supported [6–9] or refuted [10–19] by reports
on small series. It was discussed, whether it represented
an intermediate form between seminomas and nonsemi-
nomas [20]. This disagreement contributed to the uncer-
tain situation and resulted in various recommendations to
treat HCG-positive seminomas. At the Consensus Con-
ference in Hull [21] it was suggested to regard patients
with HCG values 1200 U/l as having nonseminomas.
In 1986 we initiated a prospective multicenter trial to
assess prognostic factors of seminomas with special regard
to the influence of HCG. In this paper, we want to clar-
ify the mystery surrounding HCG-positive seminomas:
(1) Do HCG-positive and negative seminomas have dif-
ferent stage distributions? (2) Do they have a different
prognostic outcome after standard therapy? (3) Are there
any other prognostic factors than HCG elevations in sem-
inomas?
Table 1. Distribution of HCG values in
HCG-positive seminomas (n = 375)
HCG, IU/l n %
182 49
20–50 61 16
50–200 68 18
200–1,000 40 11
11,000 24 6
Patients and Methods
All patients having seminomas with serologically positive HCG
entered the study. AFP-positive tumors were excluded. Between Jan-
uary 1986 and December 1991, 803 patients from 96 urological
departments were recruited, 515 of these prospectively.
77 patients had to be excluded (elevated AFP, nonseminomas,
extragonadal tumors, missing data); in 8 patients the reference
pathologist found nonseminomatous elements. 726 cases were evalu-
able. Out of them, 378 had elevated HCG levels in the cubital vein
before (n = 375) or after (n = 3) orchiectomy (table 1). 348 patients
had normal HCG values. Overall, marker determinations were per-
formed in 726 patients for HCG and AFP, in 440 for lactate dehydro-
genase (LDH) and in 174 for PIAP. The markers were determined in
local laboratories by using different commercial assays. A second
sample was sent to the study laboratory in Munich. The tumor mark-
ers were considered elevated, if the values exceeded the normal
ranges. To determine a normal/prolonged marker decay, we used
half-lives of 36 h for HCG and of 24 h for LDH and PIAP. However,
we had to consider that the markers could be evaluated only accord-
ing to the clinical stage.
For staging purposes we used the following classification: I – no
metastases; IM – no visible metastases, but elevated tumor markers
after orchiectomy: IIA – solitary lymph node metastasis !2 cm; IIB1
– multiple lymph node metastases !2 cm; IIB2 – lymph node metas-
tases 2–5 cm; IIC – lymph node metastases 15 cm, and III – lymph
node metastases above the diaphragm and/or distant metastases.
We recommended a stage-dependent therapy: stage I – infra-
diaphragmatic radiation with 30 Gy (ipsilateral iliacal lymph nodes);
stage IIA/B – infradiaphragmatic radiation with 36 Gy (with iliacal
lymph nodes included), and stages IM, IIC, and III – primary chemo-
therapy and/or surgical resection of residuals. However, RPLND and
adjuvant chemotherapy in stage IIA/B were allowed because of the
uncertainty in that stage. 84% of the patients received standard ther-
apy (radiotherapy in stage I–IIB and polychemotherapy and surgery
in case of residual tumor masses in stage IIC–III). The median radia-
tion dose was 30 (range 26–36) Gy in stage I and 36 (range 30–41) Gy
in stage IIA/B.
Statistics
For a suggested association between two continuous variables,
the linear correlation was used. Independent variables were tested by
a chi-square (Pearson test with Yates’ correction, and for special tests
with low cell counts, Fisher’s exact test was used. To illustrate differ-
ences in progression risk for stage and for HCG status, Kaplan-Meier
pT category
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curves are given. A multivariate analysis of prognostic variables
seemed not to be appropriate because the numbers of relapses were
too low (6% of the whole group). The Cox proportional hazards mod-
el was used in order to assess how a putative prognostic factor actual-
ly affects the risk of progression. As tumor stage is obviously a prog-
nostic factor, the other variables were stratified according to the four
levels ‘stage I’, ‘stage IIA’, ‘stage IIB’, and ‘stage IIC/III’. The strati-
fied relative risk estimates can be interpreted as the excess risk modi-
fication when the stage is already considered. Unstratified risk esti-
mates are given for comparison. All relative risk estimates are calcu-
lated along with confidence intervals at the local 5% level. Contin-
uous variables have been polychotomized at clinically motivated
points. Patient not receiving standard therapy have been excluded
from this analysis. Patients who developed a secondary tumor or a
contralateral testicular tumor were considered observed without pro-
gression up to that point and censored at that point.
Results
The stage distribution (for this analysis we used only
those patients who were consecutively documented in 14
of the participating hospitals) showed significant differ-
ences for HCG-positive and HCG-negative seminomas.
72% of all patients had stage I disease. HCG-positive
seminomas were more often associated with metastat-
ic disease than HCG-negative cases (37 vs. 18%, p !
0.0001), predominantly with larger retroperitoneal lymph
node metastases.
8 of 515 prospectively enrolled patients had nonsemi-
nomatous elements when the histological slides were
reviewed. Immunohistochemistry was positive in 59% of
the serologically HCG-positive seminomas.
98% of the patients are alive after a median follow-up
period of 36 months after standard therapy. 7 patients
died of their disease, and 3 patients died of therapy-relat-
ed complications (leukopenia after chemotherapy for
multiple relapses, pulmonal embolism under chemothera-
py for relapse after radiotherapy, and respiratory insuffi-
ciency after retroperitoneal lymph node dissection after
chemotherapy). 3 patients died of other causes, and a fur-
ther 2 of unknown reasons. 42 patients (6%) developed a
relapse, 22 (3%) a contralateral testis tumor, and 9 (1%) a
secondary nontesticular carcinoma.
There were no differences in the relapse-free survival
rates between HCG-positive and HCG-negative semino-
mas. Significant associations between relapse and pI cate-
gory, LDH level elevation, and metastases could be estab-
lished (table 2). The HCG level had no influence on the
prognosis of the outcome: either a simple elevation or lev-
els 1200 U/l or a prolonged marker decay. A multivariate
analysis was not done because of the small number of
relapses.
Table 2. Univariate analysis of parameters predictive for progres-
sive disease 24 months after standard therapy
Variable Patients Progres-
sion, %
p
pT1
1pT1
434
94
5
13
!0.01
Infiltration of
Rete testis no
yes
298
230
7
5
NS
Tunica albuginea no
yes
475
53
5
13
0.022
Epididymis no
yes
491
37
5
16
!0.01
Spermatic cord no
yes
500
28
6
14
!0.0061
(trend)
Vascular invasion no
yes
242
112
5
10
NS
Size of primary
tumor, cm
!3
3–6
6–10
110
126
253
123
30
2
6
6
13
0.054
(trend)
Size of primary
tumor, cm
!6
66
379
153
4
7
NS
Immunohisto-
chemistry
negative
positive
157
158
8
7
NS
HCG normal
elevated
280
321
4
7
NS
HCG level, U/l !200
1200
533
54
5
9
NS
HCG decay normal
prolonged
261
66
6
11
NS
LDH normal
elevated
245
115
3
9
0.015
LDH decay normal
prolonged
175
38
6
16
0.05
PIAP normal
elevated
47
92
0
7
0.073
(trend)
PIAP decay normal
prolonged
61
21
2
5
NS
Metastases no
yes
427
165
4
10
!0.01
Stage I
Im
IIA
IIB1
IIB2
IIC/III
427
16
42
23
15
69
4
6
2
13
33
9
!0.0001
Stage I
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Table 3. Relative risk rates for different levels of diagnostic measures, stratified according to tumor stage
Level Number
of
patients
Number of
patients with
progression
Nonstratified risk with
95% confidence interval
lower
boundary
relative
risk
upper
boundary
Stratified risk with
95% confidence interval
lower
boundary
relative
risk
upper
boundary
454 18
Stage IIA 44 1 0.1 0.6 4.2
Stage IIB 38 8 2.4 5.6 12.8
Stage IIC/III 69 7 1.2 2.8 6.7
No metastases 438 17
Metastases 167 17 1.4 2.7 5.3
Missing 61 6
Tumor size !3 cm 128 2
Tumor size 3–6 cm 262 15 0.6 1.4 3.3 0.6 1.4 3.3
Tumor size 6–10 cm 124 7 0.5 1.4 3.8 0.4 1.1 3.1
Tumor size 110 cm 26 4 0.9 3.1 10.4 0.6 2.2 8.0
Missing 65 1
pT1 444 21
pT2 68 8 1.3 3.0 6.7 1.0 2.2 5.1
pT3 28 4 1.3 3.8 10.9 0.9 2.6 8.0
Missing 65 1
Infiltration of rete testis 305 21 0.3 0.7 1.4 0.4 0.8 1.6
Missing 65 1
Infiltration of tunica albuginea 485 26 1.1 2.5 5.9 1.0 2.4 5.6
Missing 65 1
Infiltration of epididymis 503 27 1.5 3.7 8.9 0.8 2.0 5.2
Missing 65 1
Infiltration of germinal cord 512 29 1.0 2.8 8.1 0.7 2.0 6.0
Missing 243 9
No vascular invasion 247 14
Vascular invasion 115 11 0.7 1.6 3.6 0.6 1.4 3.1
Missing 61 6
Negative immunohistochemistry 164 12
Positive immunohistochemistry 158 13 0.5 1.2 2.6 0.5 1.2 2.6
HCG normal 349 15
HCG elevated 256 19 0.9 1.8 3.5 0.7 1.4 2.8
HCG !200 U/l 550 58
HCG 1200 U/l 55 6 0.9 2.1 5.1 0.7 1.7 4.5
Missing 270 11
HCG decay normal 269 15
HCG decay prolonged 66 8 0.9 2.2 5.2 0.6 1.7 4.7
Missing 234 17
LDH normal 269 15
LDH elevated 117 10 1.2 3.2 8.4 1.1 3.1 8.8
Missing 386 16
LDH decay normal 182 11
LDH decay prolonged 37 7 1.2 3.2 8.3 1.0 3.0 9.5
Missing 464 27
PIAP normal 47 0
PIAP elevated 94 7 – – – – – –
Missing 520 32
PIAP decay normal 65 1
PIAP decay prolonged 20 1 0.2 3.3 52.8 0.4 6.2 98.9
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Fig. 1. Stage-related relapse-free survival of
patients with seminomas after standard ther-
apy. EFS = Event-free survival.
Instead of this, we calculated the relative risk of devel-
opping a relapse (table 3): stage IIB had the highest risk
after radiotherapy. Moreover, an elevation of the LDH
level and its prolonged marker decay seem to be indepen-
dent predictive factors for a relapse because the relative
risk does not change when we stratify for clinical stage.
The cumulative relapse-free 3-year survival rate in
stage I was 94% for HCG-positive and 96% for HCG-neg-
ative seminomas. The results in stage IIA (one positive
node !2 cm) were similar. Patients with stage IIB had a
worse prognosis after radiotherapy, especially when the
lymph nodes exceeded 2 cm (tables 2, 3). The relapse rate
of irradiated stage IIB patients is even higher than that of
patients with more advanced stages after chemotherapy.
Comparison of the relapse rate of stage IIB patients
revealed a significant difference from patients with lower
stages and an obvious but not significant difference from
patients with higher stages (fig. 1).
Details of the relapsing patients are summarized in
table 4. 6 or 7 patients out of 9 developed their relapse
outside the retroperitoneum.
Discussion
The primary histological diagnostic error was very low,
as only 1.5% of the patients had nonseminomatous ele-
ments in the histological material reviewed. In our series,
the meticulous histological investigations resulted in a
better correlation between the serologically measured
HCG values and the immunohistochemical staining than
described in the literature. 59% of the specimens stained
positive, whereas the early publications reported on 14%
HCG-positive stainings by immunohistochemistry [5].
During the course of the study, it was shown that about
80% of the patients with seminomas had elevated HCG
values in the testicular vein, even when the samples from
the cubital vein were negative [4, 22]. Today, we have to
assume that each seminoma is able to produce HCG. This
assumption is supported by the fact that HCG could be
stained in STGC or mononuclear seminomas despite neg-
ative serum values. Thus, we have to conclude that an
HCG-positive seminoma is not a special entity.
We could demonstrate that pathological HCG levels
are correlated with the total tumor burden, i.e., the size of
the primary tumor as well as the stage of the disease [23].
Our data confirm the results of other authors who found
higher stages in seminomas with HCG or LDH elevations
[1, 24, 25].
The prognosis of HCG-positive seminomas has been a
subject of debate. Some investigators have observed the
same good results as for HCG-negative seminomas [10,
14, 16, 18, 19, 26–28], while others stated a poorer out-
come [6, 7, 17, 29–32]. Nearly all reports were based on
small, retrospectively documented series. Only the retro-
spective analysis of Mirimanoff et al. [25] attained 132
HCG-positive cases from ten centers in Switzerland.
Schwartz et al. [33] reported on 191 stage I seminomas
that could be completely reviewed, retrospectively. 13%
of them had preoperatively elevated serum levels of
HCG. All normalized after orchiectomy, and none suf-
fered a recurrence after a median follow-up period of 50
8007/01
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Table 4. Characteristics of the patients with relapse in stage IIA/B
No. Stagea HCG Radiation
Gyb
Time to
relapse
months
Localization of
relapse
Marker
AFP
Elevated
HCG
Elevated
LDH
Relapse
PIAP
Treatment
of relapse
Outcome
monthsc
IIB2 + P 42 24 mediastinum – + + ? 4 !
carboplatin
NED 52
A110/01 IIB2 + P 38 24 retroperitoneum – + + + 4 ! PEB NED 17
5600/04 IIB2 + P+S 40 4 bone ? ? + ? radiation,
surgery,
4 ! PEB
DOD
5600/08 IIB2 + P+S 36 9 marker only – + – ? 1 ! PEB,
radiation
NED 42
5600/09 IIB2 + P 36 6 bone – + ? ? 4 ! PEB DOD
2007/51 IIB1 + P 40 15 retrosternal – + – ? 3 ! PEB lost to
follow-up
7000/04 IIB2 – P 29 12 retroperitoneum ? ? ? ? surgery +
radiation
lost to
follow-up
1004/25 IIB2 – P 36 15 retroperitoneal +
pulmonal
? ? ? ? 4 ! PEB NED 48
8007/08 IIB1 – P 40 2 bone – + + – 4 ! VIP NED 45
a Stage IIB1 = Lymph node metastases !2 cm; IIB2 = lymph node metastases 2–5 cm.
b P = Periaortal; S = supradiaphragmal.
c NED = No evidence of disease; DOD = died of disease.
months. In our literature review we found no difference
between HCG-positive and HCG-negative seminomas in
stage I. A poorer outcome was demonstrated only in meta-
static (and unknown) stages.
According to our results, the prognosis was excellent
when standard therapy was applied (radiotherapy in
stages I–IIB and polychemotherapy and/or surgery for
residuals in stages IIC/III) after a median follow-up peri-
od of 36 months. Only 6% of the entire group relapsed,
and 98% are alive and free from disease. There was no
difference between HCG-positive and HCG-negative
seminomas. All stages had comparable relapse and sur-
vival rates.
In none of our analyses we found an influence of HCG
on the prognosis. This is valid for the simple preoperative
HCG elevation and values 1200 U/l as well. The limit of
200 U/l was defined at the Consensus Meeting in Hull
[21]: As to the experience of most of the participants, high
HCG titers were predominantly observed in bulky tumors
which require chemotherapy anyway. For the expected
small number of patients with seminomas with HCG
titers 1200 U/l and small metastatic lymph nodes, the
participants precautiously recommended chemotherapy.
Our results conclude this would apply to only 3% of all
seminomas and to 8% of the HCG-positive seminomas.
In contrast, patients with elevated LDH levels had a
significantly worse prognosis (p = 0.015), and those with
elevated PIAP showed a trend to a poorer outcome (p =
0.073) than patients with normal marker values. The cal-
culation of the relative risk discovered only clinical stage
and the elevation of the LDH concentration and its pro-
longed marker decay as independent prognostic factors.
Interestingly, stage IIB patients had the worst therapeutic
outcome as compared with all other stages when standard
therapy was applied. As even more advanced stages had a
more favorable outcome, it must be concluded that radio-
therapy for stage IIB seminomas should no longer be
regarded as standard therapy. After radiotherapy, the
relapse-free survival rate was only 75% for HCG-positive
and 76% for HCG-negative seminomas. A comparison
Evensen et al. [9]
Abdomen
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Table 5. Literature review of the results of radiotherapy in stage IIA/B seminoma
Authors Year of
publication
n Relapse-free
survival, %
Survival
%
Relapse rates, %
IIA IIB
1985 24 96 100 0 6
Gregory and Peckham [12] 1986 39 87 95 11 18
Zagars and Babian [36] 1987 37 95 95 ? ?
Mason and Kearsley [37] 1988 25 96 96 ? ?
Pfannmüller-Schurr et al. [35] 1988 69 88 ? 0 24
Kellokumpu-Lehtinen and Halme [15] 1990 56 82 94 ? ?
Bayens et al. [34] 1992 29 76 93 0 33
Hanks et al. [13] 1992 107 96 97 ? ?
Gospodarowicz et al. [11] 1994 56 89 96 12 9
Present series 80 87 97 2 24
Overall 522 90 96 7 22
Table 6. Relapse sites (n = 28) after radio-
therapy in stage IIA/B seminomas [11, 12,
15, 34] (multiple sites possible)
Localization n
6
Mediastinal/supraclavicular,
or supradiaphragmatic 14
Pulmonal 5
Hepatic 1
Bones 6
Miscellaneous 3
with other published results was hampered by the fact that
most radiotherapists use classifications that do not allow a
safe differentiation of stages IIA and IIB from higher
stages. Some even classify lymph node masses of up to
10 cm as IIA [8]. We summarized the data of seminomas
with low-volume metastases, considering only reports
with at least 20 cases in stage IIA/B (table 5), and found
the same trend as in our study. Patients with metastases
between 2 and 5 cm had a recurrence rate of 22% (range
6–40%) [12, 34, 35]. Most of the relapses are localized
outside the retroperitoneum (table 6), presuming a sys-
temic disease which requires systemic therapy. 30% of the
relapsing patients died of their disease. Despite the small
number of cases evaluated, we recommend chemotherapy
for these patients, especially because patients with stage
IIC/III had a better outcome after chemotherapy than
those with stage IIB after radiotherapy.
Concluding Remarks
HCG-positive seminomas have significantly higher
stages than those with normal values in the cubital vein.
HCG has no negative influence on the relapse rate of sem-
inomas. The risk of relapse is higher for patients with pT
category higher than 1 and for those with elevated LDH
levels. Obviously, seminomas – irrespective of their HCG
status – are sufficiently treated by the current standard
therapy. Therapy should only be altered in stage IIB (me-
tastases 2–5 cm), as local radiotherapy cannot prevent the
demonstrated systemic relapses. Therapy recommenda-
tions are radiotherapy for patients with clinical stages I
and IIA (no lymph node metastases or !2 cm) and chemo-
therapy for patients with lymph nodes 12 cm or distant
metastases.
Acknowledgment
This work was supported by the Ministry of Research and Tech-
nology of the Federal Republic of Germany (Grant No. 0701915).
608 Eur Urol 1999;36:601–608 Weissbach/Bussar-Maatz/Löhrs/Schubert/
Mann/Hartmann/Dieckmann/Fassbinder
References
1 Rustin GJS, Vogelzang NJ, Sleijfer DT, Nissel-
baum JN: Consensus Statement on Circulating
Tumour Markers and Staging Patients with
Germ Cell Tumours. EORTC Genitourinary
Group Monograph 7: Prostate Cancer and Tes-
ticular Cancer. New York, Wiley-Liss, 1990, pp
277–284.
2 Henkel K, Tschubel K, Bussar-Maatz R: Die
Morphologie des HCG-positiven Seminoms; in
Weissbach L, Hildenbrand G (eds): Register
und Verbund-Studie für Hodentumoren –
Bonn. Ergebnisse einer prospektiven Untersu-
chung. München, Zuckschwerdt, 1982, pp 73–
82.
3 Kurmann RJ, Scardino PT, McIntire KR,
Waldmann TA, Javadpour N: Cellular localiza-
tion of a-fetoprotein and human chorionic go-
nadotropin in germ cell tumors of the testis
using an indirect immunoperoxidase tech-
nique. Cancer 1977;40:2136.
4 Mumperow E, Hartmann M: Spermatic cord ß-
human chorionic gonadotropin levels in semi-
noma and their clinical implications. J Urol
1992;147:1041–1043.
5 Weissbach L, Bussar-Maatz R: HCG-positive
seminoma. Eur Urol 1993;23(suppl 2):29–32.
6 Butcher DN, Gregory WM, Gunter PA, Mas-
ters JRW, Parkinson MC: The biological and
clinical significance of HCG-containing cells in
seminoma. Br J Cancer 1985;51:473–478.
7 Caillaud JM, Bellet D: Etude par immunope-
roxydase de 80 tumeurs germinales testiculai-
res de l’adulte. Nouv Presse Méd 1981;10:
1057–1060.
8 Dosmann MA, Zagars GK: Post-orchiectomy
radiotherapy for stages I and II testicular semi-
noma. Int J Radiat Oncol Biol Phys 1993;26:
381–390.
9 Evensen JF, Fossa SD, Kjellevold K, Lien HH:
Testicular seminoma: Analysis of treatment
and failure for stage II disease. Radiother On-
col 1985;4:55–61.
10 Fossa A, Fossa SD: Serum lactate dehydroge-
nase and human choriogonadotrophin in semi-
noma. Br J Urol 1989;63:408–415.
11 Gospodarowicz MK, Warde PR, Pazarella T,
et al: The Princess Margaret Hospital experi-
ence in the management of stage I and II semi-
noma – 1981 to 1991; in Jones WG, Harnden
P, Appleyard I (eds): Germ Cell Tumours. Ox-
ford, Pergamon Press, 1994, vol III, pp 177–
186.
12 Gregory C, Peckham MJ: Results of radiother-
apy for stage II testicular seminoma. Radiother
Oncol 1986;6:285–292.
13 Hanks GE, Peters T, Owen J: Seminoma of the
testis: Long-term beneficial and deleterious re-
sults of radiation. Int J Radiat Oncol Biol Phys
1992;24:913–919.
14 von Hochstetter AR, Sigg C, Saremaslani P,
Hedinger C: The significance of giant cells in
human testicular seminomas. Virchows Arch A
Pathol Anat Histopathol 1985;407:309–322.
15 Kellokumpu-Lehtinen P, Halme A: Results of
treatment in irradiated testicular seminoma
patients. Radiother Oncol 1990;18:1–7.
16 Kratzik C, Kuber W: Metastasierung beim Se-
minom des Hodens mit besonderer Berück-
sichtigung des HCG-positiven Seminoms: Eine
Registerauswertung. Verhandlungsbericht der
34. Tagung der Deutschen Gesellschaft für
Urologie 1982.
17 Lang PH, Nochmovitz LE, Rosai J, et al: Se-
rum alpha-fetoprotein and human chorionic
gonadotropin in patients with seminoma. J
Urol 1980;124:473.
18 Mauch P, Weichselbaum R, Botnick L: The sig-
nificance of positive chorionic gonadotropins
in apparently pure seminoma of the testis. Int J
Radiat Oncol Biol Phys 1979;5:887–889.
19 Mirimanoff RO, Shipley WU, Dosoretz DE,
Meyer JE: Pure seminoma of the testis: The
results of radiation therapy in patients with ele-
vated human chorionic gonadotropin titers. J
Urol 1985;134:1124–1126.
20 Dieckmann KP, Düe W, Bauer HW: Semino-
ma testis with elevated serum beta-HCG – a
category of germ cell cancer between seminoma
and nonseminoma. Int Urol Nephrol 1989;21:
175–184.
21 Thomas G, Jones W, van Oosterom A, Kawai
T: Consensus statement on the investigation
and management of testicular seminoma 1989;
in Newling DWW, Jones WG (eds): Prostate
Cancer and Testicular Cancer. New York, Wi-
ley-Liss, 1990, pp 285–294.
22 Hartmann M, Pottek T, Bussar-Maatz R,
Weissbach L: Elevated HCG concentrations in
the testicular vein and in peripheral venous
blood in seminoma patients: An analysis of
various parameters. Eur Urol 1997;31:408–
413.
23 Weissbach L, Bussar-Maatz R, Mann K: The
value of tumor markers in testicular semino-
mas: Results of a prospective multicenter
study. Eur Urol 1997;32:13–19.
24 Fossa SD, Risberg T: ß-HCG producing semi-
noma; in Khoury S, Küss R, Murphy GP, Cha-
telain C, Karr JP: Testicular Cancer. New
York, Liss, 1985, pp 105–106.
25 Mirimanoff RO, Sinzig M, Kruger M, Mirabell
R, Thoni A, Ries G, Bosset JF, Bernier J, Bolla
M, Nguyen TD, et al: Prognosis of human cho-
rionic gonadotropin producing seminoma
treated by postoperative radiotherapy. Int J
Radiat Oncol Biol Phys 1993;27:17–23.
26 Bal D, Barrett A, Peckham MJ: The manage-
ment of metastatic seminoma testis. Cancer
1982;50:2289–2294.
27 Bartsch G, Mikuz G, Fommhold H, Scheiber
K: Treatment of seminoma: Does a positive
HCG influence prognosis? In Khoury S, Küss
R, Murphy GP, Chatelain C, Karr JP: Testicu-
lar Cancer. New York, Liss, 1985, pp 483–
484.
28 Swartz DA, Johnson DE, Hussey DH: Should
an elevated human chorionic gonadotropin tit-
er alter therapy for seminoma? J Urol 1984;
131:63–65.
29 Morgan DAL, Caillaud JM, Bellet D, Eschwege
F: Gonadotrophin-producing seminoma: A
distinct category of germ cell neoplasm. Clin
Radiol 1982;33:149–153.
30 Mostofi FK: Pathology of germ cell tumors of
testis: A progress report. Cancer 1980;45:
1735–1754.
31 Percarpio B, Clements JC, McLeod DG, Sor-
gen SD, Cardinale FS: Anaplastic seminoma:
An analysis of 77 patients. Cancer 1979;43:
2510–2513.
32 Roth A, le Pelletier O, Cukier L: Cryptocarci-
nome trophoblastique à cellules mononuclées
sécrétrices d’hormones gonadotrophiques cho-
rioniques bêta dans les séminomes: Valeur pro-
nostique. Presse Méd 1983;12:2801–2804.
33 Schwartz BF, Auman R, Peretsman SJ, Moul
JW, Deshon GE, Hernandez J, Rozanski TA,
Thrasher JB: Prognostic value of BHCG and
local tumor invasion in stage I seminoma of the
testis. J Surg Oncol 1996;61:131–133.
34 Bayens YC, Helle PA, Van Putten WLJ, Mali
SPM: Orchiectomy followed by radiotherapy
in 176 stage I and II testicular seminoma pa-
tients: Benefits of a 10-year follow-up study.
Radiother Oncol 1992;25:97–102.
35 Pfannmüller-Schurr EL, Hodapp N, Brugg-
moser G, Wannenmacher M: Strahlentherapie
der Seminome im Stadium II A/B; in Schmoll
HJ, Weissbach L (eds): Diagnostik und Thera-
pie von Hodentumoren. Berlin, Springer, 1988,
pp 409–414.
36 Zagars GK, Babian RJ: The role of radiation in
stage II testicular seminoma. Int J Radiat On-
col Biol Phys 1987;13:163–170.
37 Mason BR, Kearsley JH: Radiotherapy for
stage 2 testicular seminoma: The prognostic
influence of tumor bulk. J Clin Oncol 1988;6:
1856–1862.
